Long non-coding RNA (lncRNA) FAM83H-AS1 has been recently identified with oncogenic roles in many human cancers. But its role in bladder cancer (BCa) pathogenesis and the mechanisms are largely unstudied.
Bladder cancer is a common malignant tumour worldwide. Epithelial-mesenchymal transition (EMT)-related biomarkers can be used for early diagnosis and prognosis of cancer patients. To explore accurate prediction models is essential to the diagnosis and treatment for bladder cancer.
Phillip Koo: Hello, I’m Phillip Koo, and welcome to UroToday. Today we have the pleasure of speaking with Dr. Jeremie Calais who’s the Director of Clinical Research at the Ahmanson Translational Research Center at UCLA. Obviously, it’s a very exciting time for UCLA and UCSF as they were just able to get FDA approval for […]
Recent developments in prostate cancer imaging have led to a revolution in prostate cancer diagnosis, with mpMRI and MRI-targeted biopsies at the forefront. Parallelly, ultrasonography (US) has seen considerable technical advances such as including shear wave elastography, contrast-enhanced US, and high-resolution US. Among these, high-frequency micro-ultrasonography (microUS) was introduced in clinical practice in 2017.
The prevalence and biological consequences of deleterious germline variants in urothelial cancer (UC) are not fully characterized. We performed whole-exome sequencing (WES) of germline DNA and 157 primary and metastatic tumors from 80 UC patients. We developed a computational framework for identifying putative deleterious germline variants (pDGVs) from WES data. Here, we show that UC […]
Phillip Koo: Hello, welcome to UroToday. We’re very excited to have with us today Dr. Jeremie Calais, who’s the Director of Clinical Research at the Ahmanson Translational Research Center at UCLA. We’re very fortunate to have him with us today to celebrate the FDA approval of gallium 68 PSMA-11. So first off, I just wanted […]
Testicular germ cell tumors (GCT) are the most common tumor in young men. Their distinctive feature is the exceptional response to platin based combination chemotherapy.Since the prognosis is poor in relapsed and refractory patients, the immune checkpoint inhibitors are candidate agents in these patients although clinical trials are mostly lacking.
The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma.
To determine if race was associated with 5-year cause-specific survival in patients with clear cell renal cell carcinoma. Outcomes were investigated using the Surveillance Epidemiology and End Results (SEER) database with data from 13 states between the years 2007-2015.
Increased attention has been focused on the survival of renal cell carcinoma (RCC) patients with bone metastasis. This study proposed to establish and evaluate a nomogram for predicting the overall survival (OS) and cancer-specific survival (CSS) of RCC patients with bone metastasis.
